BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar S, Singh B, Kumari P, Kumar PV, Agnihotri G, Khan S, Kant Beuria T, Syed GH, Dixit A. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. Comput Struct Biotechnol J 2021;19:1998-2017. [PMID: 33841751 DOI: 10.1016/j.csbj.2021.04.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Dai J, Wang H, Liao Y, Tan L, Sun Y, Song C, Liu W, Qiu X, Ding C. Coronavirus Infection and Cholesterol Metabolism. Front Immunol 2022;13:791267. [DOI: 10.3389/fimmu.2022.791267] [Reference Citation Analysis]
2 Urda L, Kreuter MH, Drewe J, Boonen G, Butterweck V, Klimkait T. The Petasites hybridus CO2 Extract (Ze 339) Blocks SARS-CoV-2 Replication In Vitro. Viruses 2022;14:106. [PMID: 35062310 DOI: 10.3390/v14010106] [Reference Citation Analysis]
3 Jamir E, Sarma H, Priyadarsinee L, Nagamani S, Kiewhuo K, Gaur AS, Rawal RK, Murugan NA, Subramanian V, Sastry GN. Applying polypharmacology approach for drug repurposing for SARS-CoV2. J Chem Sci 2022;134. [DOI: 10.1007/s12039-022-02046-0] [Reference Citation Analysis]
4 Piplani S, Singh P, Petrovsky N, Winkler DA. Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies. Front Mol Biosci 2022;9:781039. [DOI: 10.3389/fmolb.2022.781039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Singh B, Avula K, Chatterjee S, Datey A, Ghosh A, De S, Keshry SS, Ghosh S, Suryawanshi AR, Dash R, Senapati S, Beuria TK, Prasad P, Raghav S, Swain R, Parida A, Hussain Syed G, Chattopadhyay S. Isolation and Characterization of Five Severe Acute Respiratory Syndrome Coronavirus 2 Strains of Different Clades and Lineages Circulating in Eastern India. Front Microbiol 2022;13:856913. [DOI: 10.3389/fmicb.2022.856913] [Reference Citation Analysis]
6 Kao HT, Orry A, Palfreyman MG, Porton B. Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19. Sci Rep 2022;12:10174. [PMID: 35715434 DOI: 10.1038/s41598-022-14194-x] [Reference Citation Analysis]
7 Durdagi S, Avsar T, Orhan MD, Serhatli M, Balcioglu BK, Ozturk HU, Kayabolen A, Cetin Y, Aydinlik S, Bagci-Onder T, Tekin S, Demirci H, Guzel M, Akdemir A, Calis S, Oktay L, Tolu I, Butun YE, Erdemoglu E, Olkan A, Tokay N, Işık Ş, Ozcan A, Acar E, Buyukkilic S, Yumak Y. The neutralization effect of montelukaston SARS-CoV-2 is shown by multiscale in silicosimulations and combined in vitro studies. Mol Ther 2021:S1525-0016(21)00521-9. [PMID: 34678509 DOI: 10.1016/j.ymthe.2021.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
8 Pandolfi S, Chirumbolo S, Ricevuti G, Valdenassi L, Bjørklund G, Lysiuk R, Doşa MD, Lenchyk L, Fazio S. Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal. Basic Clin Pharmacol Toxicol 2021. [PMID: 34811895 DOI: 10.1111/bcpt.13690] [Reference Citation Analysis]
9 May BC, Gallivan KH. Levocetirizine and montelukast in the COVID-19 treatment paradigm. Int Immunopharmacol 2021;103:108412. [PMID: 34942461 DOI: 10.1016/j.intimp.2021.108412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Radder SB, Melavanki R, Hiremath SM, Kusanur R, Khemalapure SS, Jeyaseelan SC. Synthesis, spectroscopic (FT-IR, FT-Raman, NMR & UV-Vis), reactive (ELF, LOL, Fukui), drug likeness and molecular docking insights on novel 4-[3-(3-methoxy-phenyl)-3-oxo-propenyl]-benzonitrile by experimental and computational methods. Heliyon 2021;7:e08429. [PMID: 34877424 DOI: 10.1016/j.heliyon.2021.e08429] [Reference Citation Analysis]